Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - AEterna Laboratories, Inc (NasdaqNM:AELA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | Msgs
Recent Events
Aug 22Price hit new 52-week low ($5.21)
Location
1405 Parc-Technologique Blvd.
Quebec, G1P 4P5
Quebec, Canada
Phone: (418) 652-8525
Fax: (418) 652-0881
Email: aeterna@aeterna.com
Employees (last reported count): 150
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 17%
·Institutional: 1% (1% of float)
(10 institutions)
·Net Inst. Buying: 140.0K shares (+35.91%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
AEterna Laboratories Inc. is a biopharmaceutical company focused on the development of new therapeutics for unmet medical needs, principally cancer. AEterna's lead compound, AE-941, is an angiogenesis inhibitor in clinical trials in three major indications: oncology, dermatology and ophthalmology. AE-941/Neovastat is entering its pivotal stage of development with, among others, a Phase III trial for the treatment of lung cancer in collaboration with the U.S. National Cancer Institute (NCI). AEterna's strategy is to build a portfolio of complementary technologies that will leverage its resources and expertise in drug development and target diseases with significant market potential. AEterna, through its subsidiary Atrium Biotechnologies, is also involved in the development of active ingredients for use in cosmetics and nutritional supplements.
More from Market Guide: Expanded Business Description

Financial Summary
AELA is a Canadian biopharmaceutical company. The Company's lead product, Neovastat, is the focus of a number of clinical trials for the treatment of lung and kidney cancer. For the six months ended 6/30/01, revenues rose 35% to C$5.4 million. Net income totaled C$4.3 million vs. a loss of C$3.8 million. Revenues reflect increased sales in the U.S. and Asia and a benefit from an acquisition. Net income reflects an increase in research and development tax credits.
More from Market Guide: Significant Developments

Officers

Position
Eric Dupont, Ph.D.Chairman, Pres, CEO
Gilles GagnonCOO, VP
Luc DupontExec. VP, Director
Dennis TurpinVP, CFO
Claude VadboncoeurVP- Legal Affairs, Sec.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:AELAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Aug-2001
$5.21 
Recent Price$5.30 
52-Week High
on 6-June-2001
$8.68 
Daily Volume (3-month avg)6,545 
Daily Volume (10-day avg)6,000 
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
13-Week Change-30.3%
13-Week Change
relative to S&P500
-22.4%
Share-Related Items
Market Capitalization$159.6M
Shares Outstanding30.1M
Float25.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.50 
Earnings (ttm)$0.04 
Earnings (mrq)$0.15 
Sales (ttm)$0.20 
Cash (mrq)$1.30 
Valuation Ratios
Price/Book (mrq)3.53 
Price/Earnings (ttm)117.78 
Price/Sales (ttm)26.26 
Income Statements
Sales (ttm)$6.32M
EBITDA (ttm)-$8.41M
Income available to common (ttm)$1.47M
Profitability
Profit Margin (ttm)23.3%
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)2.43%
Return on Equity (ttm)3.27%
Financial Strength
Current Ratio (mrq)11.99 
Debt/Equity (mrq)0.07 
Total Cash (mrq)$39.0M
Short Interest
As of 8-Aug-2001
Shares Short13.0K
Percent of Float0.1%
Shares Short
(Prior Month)
2,000 
Short Ratio2.17 
Daily Volume6,000 
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001);   dollar amounts based on an exchange rate of 1.55 Canadian Dollars/US Dollar

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.